OBI Pharma is developing novel therapeutic agents
for unmet medical needs in cancer

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development overview at the 39th Annual J.P. Morgan Digital Healthcare Conference on Monday, January 11, 2021 at 11:00 a.m. EST/ 8:00 …

詳細閱讀

ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

1. Presentation number: 397P / Poster: ID 680 Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients Presenter: Ching-Liang Ho MD, et.al. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. Session Title: E-poster Display session – Thoracic tumours, metastatic Session Date and Time: …

詳細閱讀

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort TAIPEI, Taiwan, November 19, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4), today announced that data from …

詳細閱讀